CD33 and acute myeloid leukemia: Since the first phase I clinical trial was published in 1991 demonstrating the feasibility of using 131I-labelled anti-CD33 Ab in patients with relapsed AML (143), several clinical studies have explored antibodies carrying β– or α-particle emitters, alone or as part of a conditioning regimen for stem cell transplantation in patients with relapsed AML.